333 related articles for article (PubMed ID: 30933897)
1. Target exposure and pharmacodynamics study of the indoleamine 2,3-dioxygenase-1 (IDO-1) inhibitor epacadostat in the CT26 mouse tumor model.
Poncelet L; Ait-Belkacem R; Marillier R; Gomes B; Stauber J
J Pharm Biomed Anal; 2019 Jun; 170():220-227. PubMed ID: 30933897
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies.
Shi JG; Bowman KJ; Chen X; Maleski J; Leopold L; Yeleswaram S
J Clin Pharmacol; 2017 Jun; 57(6):720-729. PubMed ID: 27990653
[TBL] [Abstract][Full Text] [Related]
3. Determination of kynurnine and tryptophan, biomarkers of indoleamine 2,3-dioxygenase by LC-MS/MS in plasma and tumor.
Wang W; Zhuang X; Liu W; Dong L; Sun H; Du G; Ye L
Bioanalysis; 2018 Aug; 10(16):1335-1344. PubMed ID: 30130131
[TBL] [Abstract][Full Text] [Related]
4. First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies.
Beatty GL; O'Dwyer PJ; Clark J; Shi JG; Bowman KJ; Scherle PA; Newton RC; Schaub R; Maleski J; Leopold L; Gajewski TF
Clin Cancer Res; 2017 Jul; 23(13):3269-3276. PubMed ID: 28053021
[No Abstract] [Full Text] [Related]
5. Microenvironment Tumor Metabolic Interactions Highlighted by qMSI: Application to the Tryptophan-Kynurenine Pathway in Immuno-Oncology.
Ait-Belkacem R; Bol V; Hamm G; Schramme F; Van Den Eynde B; Poncelet L; Pamelard F; Stauber J; Gomes B
SLAS Discov; 2017 Dec; 22(10):1182-1192. PubMed ID: 28557618
[TBL] [Abstract][Full Text] [Related]
6. Interferon-Induced IDO1 Mediates Radiation Resistance and Is a Therapeutic Target in Colorectal Cancer.
Chen B; Alvarado DM; Iticovici M; Kau NS; Park H; Parikh PJ; Thotala D; Ciorba MA
Cancer Immunol Res; 2020 Apr; 8(4):451-464. PubMed ID: 32127391
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of S-EPA, and its inhibition on indoleamine 2,3-dioxgenase: a case of sulfur-substitution affecting distributions in blood cells.
Wang W; Zhuang X; Sun H; Dong L; Liu Z; Du G; Ye L; Tian J
Xenobiotica; 2019 Nov; 49(11):1338-1343. PubMed ID: 30507339
[TBL] [Abstract][Full Text] [Related]
8. Comparison study of different indoleamine-2,3 dioxygenase inhibitors from the perspective of pharmacodynamic effects.
Jiang X; Li X; Zheng S; Du G; Ma J; Zhang L; Wang H; Tian J
Int J Immunopathol Pharmacol; 2020; 34():2058738420950584. PubMed ID: 32962460
[TBL] [Abstract][Full Text] [Related]
9. Mass spectrometric measurement of urinary kynurenine-to-tryptophan ratio in children with and without urinary tract infection.
Yarbrough ML; Briden KE; Mitsios JV; Weindel AL; Terrill CM; Hunstad DA; Dietzen DJ
Clin Biochem; 2018 Jun; 56():83-88. PubMed ID: 29679555
[TBL] [Abstract][Full Text] [Related]
10. The IDO1 selective inhibitor epacadostat enhances dendritic cell immunogenicity and lytic ability of tumor antigen-specific T cells.
Jochems C; Fantini M; Fernando RI; Kwilas AR; Donahue RN; Lepone LM; Grenga I; Kim YS; Brechbiel MW; Gulley JL; Madan RA; Heery CR; Hodge JW; Newton R; Schlom J; Tsang KY
Oncotarget; 2016 Jun; 7(25):37762-37772. PubMed ID: 27192116
[TBL] [Abstract][Full Text] [Related]
11. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
Labadie BW; Bao R; Luke JJ
Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
[TBL] [Abstract][Full Text] [Related]
12. Hydroxyamidine inhibitors of indoleamine-2,3-dioxygenase potently suppress systemic tryptophan catabolism and the growth of IDO-expressing tumors.
Koblish HK; Hansbury MJ; Bowman KJ; Yang G; Neilan CL; Haley PJ; Burn TC; Waeltz P; Sparks RB; Yue EW; Combs AP; Scherle PA; Vaddi K; Fridman JS
Mol Cancer Ther; 2010 Feb; 9(2):489-98. PubMed ID: 20124451
[TBL] [Abstract][Full Text] [Related]
13. IDO1 Inhibition Overcomes Radiation-Induced "Rebound Immune Suppression" by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Li A; Barsoumian HB; Schoenhals JE; Caetano MS; Wang X; Menon H; Valdecanas DR; Niknam S; Younes AI; Cortez MA; Welsh JW
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):903-912. PubMed ID: 30905636
[TBL] [Abstract][Full Text] [Related]
14. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain.
Mazarei G; Budac DP; Lu G; Lee H; Möller T; Leavitt BR
Exp Neurol; 2013 Nov; 249():144-8. PubMed ID: 23994717
[TBL] [Abstract][Full Text] [Related]
15. Canine mast cell tumour cells regulate tryptophan catabolism via the expression of indoleamine 2,3-dioxygenase.
Matsuda A; Hata A; Tanaka A; Matsuda H
Res Vet Sci; 2021 Jul; 137():159-162. PubMed ID: 33984619
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of 1,2,5-oxadiazole-3-carboximidamide derivatives as novel indoleamine-2,3-dioxygenase 1 inhibitors.
Song X; Sun P; Wang J; Guo W; Wang Y; Meng LH; Liu H
Eur J Med Chem; 2020 Mar; 189():112059. PubMed ID: 31981851
[TBL] [Abstract][Full Text] [Related]
17. Indoleamine 2,3-dioxygenase gene expression and kynurenine to tryptophan ratio correlation with nasopharyngeal carcinoma progression and survival.
Souissi S; Ghedira R; Macherki Y; Ben-Haj-Ayed A; Gabbouj S; Remadi Y; Sfar I; Chadli Z; Aouam K; Hassine M; Bouaouina N; Zakhama A; Hassen E
Immun Inflamm Dis; 2022 Sep; 10(9):e690. PubMed ID: 36039641
[TBL] [Abstract][Full Text] [Related]
18. A peripheral blood mononuclear cell-based in vitro model: A tool to explore indoleamine 2, 3-dioxygenase-1 (IDO1).
Gonçalves M; Furgiuele A; Rasini E; Legnaro M; Ferrari M; Luini A; Rodrigues-Santos P; Caramelo F; Marino F; Pereira FC; Cosentino M
Eur J Pharmacol; 2024 Apr; 968():176420. PubMed ID: 38367683
[TBL] [Abstract][Full Text] [Related]
19. Enhanced tryptophan-kynurenine metabolism via indoleamine 2,3-dioxygenase 1 induction in dermatomyositis.
Wu D; Chen M; Chen S; Zhang S; Chen Y; Zhao Q; Xue K; Xue F; Chen X; Zhou M; Li H; Zheng J; Le Y; Cao H
Clin Rheumatol; 2022 Oct; 41(10):3107-3117. PubMed ID: 35778590
[TBL] [Abstract][Full Text] [Related]
20. 4-Bromophenylhydrazinyl benzenesulfonylphenylureas as indoleamine 2,3-dioxygenase inhibitors with in vivo target inhibition and anti-tumor efficacy.
Lin SY; Yeh TK; Song JS; Hung MS; Cheng MF; Liao FY; Li AS; Cheng SY; Lin LM; Chiu CH; Wu MH; Lin YJ; Hsiao W; Sun M; Wang YH; Huang CH; Tang YC; Chang HH; Huang ZT; Chao YS; Shih C; Pan SL; Wu SY; Kuo CC; Ueng SH
Bioorg Chem; 2018 Apr; 77():600-607. PubMed ID: 29494816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
